(12) Patent Application Publication (10) Pub. No.: US 2005/0049256A1 Lorton Et Al

Total Page:16

File Type:pdf, Size:1020Kb

(12) Patent Application Publication (10) Pub. No.: US 2005/0049256A1 Lorton Et Al US 2005.0049256A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0049256A1 LOrton et al. (43) Pub. Date: Mar. 3, 2005 (54) TREATMENT OF INFLAMMATORY Publication Classification AUTOIMMUNE DISEASES WITH ALPHA-ADRENERGIC ANTAGONSTS AND BETA-ADRENERGICAGONSTS (51) Int. Cl." ...................... A61K 31/517; A61K 31/137 (76) Inventors: Dianne Lorton, Avondale, AZ (US); (52) U.S. Cl. ..................... 514/252.17; 514/649; 514/651 Cheri Lubahn, Glendale, AZ (US) Correspondence Address: JENNINGS, STROUSS & SALMON, P.L.C. (57) ABSTRACT 201 E. WASHINGTON ST, 11TH FLOOR PHOENIX, AZ 85004 (US) The present invention discloses a novel compound and (21) Appl. No.: 10/928,437 method for the treatment of inflammatory autoimmune dis eases, for example, rheumatoid arthritis, using C.-adrenergic (22) Filed: Aug. 27, 2004 antagonists and B-adrenergic agonists in combination. Treat ment of animals, namely humans, with an O-adrenergic Related U.S. Application Data antagonist, preferably, phentolamine, and a B-adrenergic agonist, preferably terbutaline, in combination can Signifi (60) Provisional application No. 60/498.367, filed on Aug. cantly Suppress the joint destruction and inflammation due to 27, 2003. disease in these animals. Patent Application Publication Mar. 3, 2005 Sheet 1 of 5 US 2005/0049256A1 Patent Application Publication Mar. 3, 2005 Sheet 2 of 5 US 2005/0049256A1 e \ s o o (ulu) pA ped)00 IBuedos. IOC Patent Application Publication Mar. 3, 2005 Sheet 3 of 5 US 2005/0049256A1 as o N w N o et N O CY) c5 O t al L cN Y D. a s t is r s re y (uu) supW pedoo Patent Application Publication US 2005/004925.6 A1 |0*>d 0|| eIOOS 3 guide foupe Patent Application Publication Mar. 3, 2005 Sheet 5 of 5 US 2005/0049256A1 w { Z w t n e (%) (Sudawn,0A US 2005/0049256 A1 Mar. 3, 2005 TREATMENT OF INFLAMMATORY DMARDS. Use of one second-line drug followed by another AUTOIMMUNE DISEASES WITH once the drug being used is no longer effective or is not ALPHA-ADRENERGIC ANTAGONSTS AND tolerated well by the patient, is most widely practiced by BETA-ADRENERGICAGONSTS rheumatologists. Methotrexate and other immunosuppres Sive drugs, Such as cycloSporin and leflunomide were major CLAIM TO DOMESTIC PRIORITY advancements of the 1980s in treating rheumatoid arthritis. Methotrexate is currently the gold standard for treatment of 0001. This Application claims the benefit of priority of aggressive rheumatoid arthritis. However, its effectiveness U.S. Application Ser. No. 60/498.367, filed Aug. 27, 2003. wanes over time and can cause troublesome side effects, including liver damage, Sepsis, Severe anemia and bleeding. FIELD OF THE INVENTION 0007. The approved immunosuppressive drug, lefluno 0002 The present invention relates to an improved mide, was introduced for treating rheumatoid arthritis. This method for the treatment of inflammatory autoimmune dis drug relieves joint tenderneSS and Swelling, decreases joint ease, and more Specifically to a treatment for inflammatory pain and reduces indicators of global disease activity. While autoimmune disease, including rheumatoid arthritis, using leflunomide does not make patients more Susceptible to C.-adrenergic antagonists and B-adrenergic agonists in com infections, it can cause hair loSS, weight loss, hypertension, bination. diZZiness, and gastrointestinal Side effects. Advances in management of rheumatoid arthritis include the use of BACKGROUND OF THE INVENTION corticosteroids as anti-inflammatory and immunosuppres Sive agents. The main disadvantage of corticosteroids is that 0003 Rheumatoid arthritis (RA) is a chronic inflamma long-term use is limited due to adverse effects including tory autoimmune disease of the joints, producing pain and Weight gain, hyperglycemia, cataracts, Osteoporosis, and ultimate destruction of the joints. Rheumatoid arthritis is characterized by a chronic inflammatory response in the Stomach ulcers. joint that is directed by macrophages and T cells which 0008 Thus, treatment for patients with rheumatoid arthri invade affected joints. Production of proinflammatory cytok tis is imperfect. Accordingly, there is an urgent need for ines and other immune cell mediators by these immune cells treatments which have few if any side effects and that will results in the development of a proliferative invasive con be effective in Suppressing not only the inflammation but nective tissue derived from the Synovial membrane and its also prevent the bone and cartilage degeneration associated microvasculature that slowly erodes away the cartilage and with rheumatoid arthritis. bone tissues of joints. SUMMARY OF THE INVENTION 0004. While destruction of joint tissue is the most com mon feature of RA, the disease can exhibit significant 0009. The present invention discloses a method for the extra-articular manifestations, including cutaneous lesions, treatment of inflammatory autoimmune diseases by admin vasculitis, blood abnormalities, peripheral neuropathy, peri istering B-adrenergic agonists in combination with C.-adren carditis, arteritis of the Viscera, and pulmonary disease. This ergic antagonists. The present invention further discloses a indicates that RA is a Systemic disease that affects the compound useful in treating inflammatory autoimmune dis connective tissueS of major organs Systems. The Specific eases comprising B-adrenergic agonists in combination with etiology of RA remains elusive. Dysregulation of both C.-adrenergic antagonists. cell-mediated and humoral immunity are associated with 0010. In certain embodiments, the present invention con RA. The pathophysiology of RA intimately involves defects cerns a compound and method for treating rheumatoid in immune cell regulation. Although the exact mechanisms arthritis or other autoimmune diseases, Such as inflammatory have not been delineated, the functional activities of mac bowel disease, Krohn's disease, thyroiditis, fibromyalgia, rophages, B cells and T cells from both the joint and Systematic erythermatus, lupus, chronic fatigue Syndrome, lymphoid tissue are affected. and Type 1 diabetes, by the application of a therapeutically 0005. Unfortunately, current treatment strategies for RA effective dose of a f-adrenergic agonist, preferably a f-adr and other inflammatory autoimmune diseases are relatively energic agonist Such as terbutaline, coupled with a thera ineffective in preventing bone destruction. Conventional peutically effective dose of an O-adrenergic antagonist, anti-rheumatic drugs are classified into anti-inflammatory preferably C-, C., and C2-adrenergic receptor Subtypes Such drugs, Slow-acting drugs and corticosteroids. Only the slow as phentolamine, praZosin or yohimbine, to human Subjects acting drugs are thought to be capable of modifying the with the disease. Therapeutically effective doses of particu disease course of rheumatoid arthritis and are referred to as lar agonists or antagonists and the frequency of dosage disease modifying anti-rheumatic drugs (DMARD). Drugs administration are to be determined according to protocols from each of these classes are currently being used for understood by those skilled in the art. treatment of rheumatic diseases. Of these, the central focus 0011. Other B-adrenergic agonists useful in this novel has been and remains the DMARDS and nonsteroidal anti method of treatment include: metaproterenol, albuterol, iso inflammatory drugs (NSAID). NSAIDs effectively abolish etharine, pributerol, bitolterol, ritodrine, and Salmeterol. the Signs and Symptoms of joint inflammation and reduce Other C.-adrenergic antagonists useful in this novel method pain. They are not effective in preventing bone and cartilage of treatment include: yohimbine, regitine, prazosin, dox loss. The value of NSAIDs for treating rheumatic diseases is aZosin, tamsulosin, teraZosin, octopamine, phenoxyben limited by their side effects. Zamine, phentolamine, hydrochlorothiazide, 5-methyl ura 0006 Aggressive rheumatoid arthritis or early onset of pidil, chloroethylclonidine, bunazosin, alfuzosin, RS17053, joint destruction indicates the need for rapid treatment with BMY 7378, urapidil, L-765,314, nicergoline, ABT-866, US 2005/0049256 A1 Mar. 3, 2005 cyclazosin, A322312, A 119637, fiduxosin, JTH-601, imi 0018 FIG. 2 is a graph depicting the decreased dor loxan, 2 idopropoxyidazoxan, 2-methoxyidazoxan (RX Soplantar Swelling by day 28 in animals treated with vehicle, 821002), idazoxan, piperoxan, BRL 44408, beditin, atipam phentolamine and/or trebutaline. eZole, rawolscine, ARC 239, RS-79948, MK912, RS 79948, 0019 FIG. 3 illustrates the results of continuous treat UIC 14304 and ethoxyidazoxan. ment with vehicle, combination phentolamine/terbutaline, 0012. The f-adrenergic agonists and C.-adrenergic combination yohimbine/terbutaline or combination pra antagonists of the present invention may be administered to ZoSine/terbutiline drug therapies from initiated at disease a patient in a dosage form Selected from the group consisting onset, day 12 post-CFA challenge, and continued through of pills, tablets, capsules, caplets, Solutions, Suspensions, day 28, that reduced dorsoplantar footpad widths in arthritic Syrups, Suppositories, and aerosols. Additionally, the dosage rats when compared with vehicle treated controls. of the ?- (or f3-) and C.- (or C- or Cl-) adrenergic agonist 0020 FIGS. 4A-E shows the radiographic analysis of and antagonist, respectively, used may be in a Sustained ankle joints treated with vehicle and adrenergic drug com release form. The dosage form of the B-adrenergic agonist
Recommended publications
  • ALPHA ADRENOCEPTORS and HUMAN SEXUAL FUNCTION Alan
    8 1995 Elsevier Science B. V. All rights reserved. The Pharmacology of Sexual Function and Dysfunction J. Bancroft, editor 307 ALPHA ADRENOCEPTORS AND HUMAN SEXUAL FUNCTION Alan J Riley Field Place, Dunsmore, Buckinghamshire, HP22 6QH, UK Introduction Sexual functioning involves complex physiological processes which rely on the interplay of many central and peripheral neurotransmitter systems. Disturbances in any one of these systems might be associated with disturbed sexual function which, when recognised, may be alleviated by appropriate pharmacological manipulation, although at the present time this is more hypothesis than reality, The sympathetic nervous system is involved actively at various levels in the normal control of sexual responses. The effects of sympathetic activation are mediated by the release of noradrenaline from nerve terminals and the increased secretion of adrenaline from the adrenal medulla. These catecholamines selectively activate specific cellular sites in target tissues known as adrenoceptors (previously termed adrenergic receptors) to mediate responses. Almost fifty years ago, Alquist realised that tissue responses to catecholamines were mediated through two distinct types of receptors which he designated a and/? [1]. This review focuses on the involvement of a-adrenoceptors in human sexual functioning and dysfunction. Alpha adrenoceptors are located both pre- and post- synaptically and they were classified as either ar or af adrenoceptors according to location; or, being postsynaptic and az presynaptic. This classification continues to be used in some texts. However, as highly specific and selective pharmacological tools became available, this locational subclassification is found not always to be appropriate. Nowadays, classification of a-adrenoceptors is more appropriately based on pharmacological activity and additional subtypes of a-adrenoceptors have been identified by radioligand binding and molecular biological techniques [2].
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Antihypertensive Agents Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Antihypertensive Agents Using ALZET Osmotic Pumps 1. Atenolol Q7652: W. B. Zhao, et al. Stimulation of beta-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British Journal of Pharmacology 2019;176(14):2465-2481 Agents: Isoproterenol; propranolol; carvedilol; atenolol; ICI-118551 Vehicle: saline; ascorbic acid, buffered; Route: SC; Species: Mice; Pump: 2001; Duration: 1 day; 2 days; 7 days; ALZET Comments: Dose ((ISO 0.6, 6, 20 mg/kg/d), (Prop 2 mg/kg/d), (Carv 2 mg/kg/d), (AT 2 mg/kg/d), (ICI 1 mg/kg/d)); saline with 0.4 mM ascorbic acid used; Controls were non-transgenic and received mp w/ vehicle; animal info (12-16 weeks, Male, (C57BL/6J, beta2-TG, Mst1-TG, or dnMst1-TG)); ICI-118551 is a beta2-antagonist with the structure (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; cardiovascular; Minipumps were removed to allow for washout of ISO overnight prior to imaging; Q7241: M. N. Nguyen, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 2018;8(1):8213 Agents: Isoproterenol, Atenolol, ICI-118551 Vehicle: Saline, ascorbic acid; Route: SC; Species: Mice; Pump: Not Stated; Duration: 48 Hours; ALZET Comments: Dose: ISO (2, 6 or 30 mg/kg/day; atenolol (2 mg/kg/day), ICI-118551 (1 mg/kg/day); 0.4 mM ascorbic used; animal info (12 14 week-old C57Bl/6 mice); cardiovascular; Q6161: C.
    [Show full text]
  • And Antagonists Between the Pithed Rabbit and Rat J.M
    Br. J. Pharmac. (1987), 91, 457-466 Difference in the potency ofa2-adrenoceptor agonists and antagonists between the pithed rabbit and rat J.M. Bulloch, 'J.R. Docherty, 2N.A. Flavahan, J.C. McGrath & C.E. McKean Institute ofPhysiology, University ofGlasgow, Glasgow G12 8QQ, Scotland 1 The subtypes ofa-adrenoceptors which mediate pressor responses to sympathomimetic agonists or to nerve stimulation in pithed rabbits have been classified according to the effects of 'selective' antagonists and a comparison has been made, for the xt2-subtype, with corresponding responses in the rat. 2 In the rabbit the dose-response curve for phenylephrine was shifted to the right in parallel by prazosin (1 mg kg-') and was unaffected by rauwolscine (1 mg kg '). The dose-response curve for noradrenaline was shifted to the right by prazosin (I mg kg -') and was shifted to a smaller extent by rauwolscine (1 mg kg -') or imiloxan (1Omg kg-'). After rauwolscine, prazosin produced a rightward shift larger than when given alone. After prazosin, rauwolscine produced a rightward shift larger than when given alone. 3 The responses to pressor nerve stimulation at low frequencies (< 1 Hz) could be reduced by prazosin, rauwolscine or imiloxan but those at a higher frequency could be reduced only by prazosin. 4 These results indicate that the responses to noradrenaline or to nerve stimulation are mediated by both a,- and a2-adrenoceptors. Low doses or frequencies have a proportionately greater component which is M2 5 Responses to noradrenaline after prazosin (1 mg kg -'), were sufficiently sensitive to rauwolscine to be considered as predominantly a2.
    [Show full text]
  • And Α2-Adrenoceptor Subtypes in the Vasopressor Responses Induced by Dihydroergotamine in Ritanserin-Pretreated Pithed Rats Eduardo Rivera-Mancilla1, Victor H
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Erasmus University Digital Repository Rivera-Mancilla et al. The Journal of Headache and Pain (2017) 18:104 The Journal of Headache DOI 10.1186/s10194-017-0812-4 and Pain RESEARCHARTICLE Open Access The role of α1- and α2-adrenoceptor subtypes in the vasopressor responses induced by dihydroergotamine in ritanserin-pretreated pithed rats Eduardo Rivera-Mancilla1, Victor H. Avilés-Rosas1, Guadalupe Manrique-Maldonado1, Alain H. Altamirano-Espinoza1, Belinda Villanueva-Castillo1, Antoinette MaassenVanDenBrink2 and Carlos M. Villalón1* Abstract Background: Dihydroergotamine (DHE) is an acute antimigraine agent that displays affinity for dopamine D2-like receptors, serotonin 5-HT1/2 receptors and α1/α2-adrenoceptors. Since activation of vascular α1/α2-adrenoceptors results in systemic vasopressor responses, the purpose of this study was to investigate the specific role of α1- and α2-adrenoceptors mediating DHE-induced vasopressor responses using several antagonists for these receptors. Methods: For this purpose, 135 male Wistar rats were pithed and divided into 35 control and 100 pretreated i.v. with ritanserin (100 μg/kg; to exclude the 5-HT2 receptor-mediated systemic vasoconstriction). Then, the vasopressor responses to i.v. DHE (1–3100 μg/kg, given cumulatively) were determined after i.v. administration of some α1/α2-adrenoceptor antagonists. Results: In control animals (without ritanserin pretreatment), the vasopressor responses to DHE were: (i) unaffected after prazosin (α1;30μg/kg); (ii) slightly, but significantly, blocked after rauwolscine (α2;300μg/kg); and (iii) markedly blocked after prazosin (30 μg/kg) plus rauwolscine (300 μg/kg).
    [Show full text]
  • α2-Adrenoceptor and 5-Ht3 Serotonin Receptor
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 α2-ADRENOCEPTOR AND 5-HT3 SEROTONIN RECEPTOR LIGANDS AS POTENTIAL ANALGESIC ADJUVANTS Genevieve Alley Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2867 This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. © Genevieve Sirles Alley 2012 All Rights Reserved i α2-ADRENOCEPTOR AND 5-HT3 SEROTONIN RECEPTOR LIGANDS AS POTENTIAL ANALGESIC ADJUVANTS A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy at Virginia Commonwealth University. by Genevieve Sirles Alley Bachelor of Science in Biology, Virginia Commonwealth University 2005 Director: Małgorzata Dukat, Ph.D. Associate Professor, Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia August 2012 ii ACKNOWLEDGMENT First, I would like to thank Dr. Małgorzata Dukat for her continued assistance and advice throughout my studies. This guidance has helped me better understand and appreciate medicinal chemistry. Also, a special thanks is given to both Dr. Dukat and Dr. Richard A. Glennon for their constant quizzing during group meetings, which not only helped me recongnize what I did not already understand, but also, improved my ability to devise potential solutions for future research problems. Furthermore, I could not have successfully completed this dissertation work without the help of Dr.
    [Show full text]
  • Dual Mechanism Analgesia-Enhancing Agents
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2005 Dual Mechanism Analgesia-Enhancing Agents Shawquia Elithia Young Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Chemicals and Drugs Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/1166 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. O Shawquia Elithia Young, 2005 All Rights Reserved DUAL MECHANISM ANALGESIA-ENHANCING AGENTS A thesis submitted in partial fulfillment of the requiremehts for the degree of Master of Science at Virginia Commonwealth University. Shawquia Elithia Young Bachelor of Science, Hampton University, 2002 Director: Malgorzata Dukat, Ph.D. Department of Medicinal Chemistry Co-Director: Richard A. Glennon, Ph.D. Department of Medicinal Chemistry Virginia Commonwealth University Richmond, Virginia August 2005 Acknowledgements I would like to express my deepest gratitude to my'advisors Dr. Malgorzata Dukat and Dr. Richard Glennon for their wonderful guidance and teachings in the completion of this research. Their patience and honesty were greatly appreciated. I am also thankful to Dr. Anna Wesolowska for teaching me everything about the mouse tail-flick and hot- plate assays. I would like to thank Dr. Eliseu De Oliveira for being optimistic and patient while helping me in my synthesis. I want to give thanks to Dr. Richard Young for providing me with guidance in working with the locomotor activity assay.
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer prfritar. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand comer and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9211148 Synthesis and biological results of compounds acting on alpha-adrenergic receptors Hong, Seoung Soo, Ph.D. The Ohio State University, 1991 Copyright ©1991 by Hong, Seoung Soo.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]